Stock

LENZ Therapeutics, Inc. LENZ

$5.34+6.06%

All stocks Create account to unlock

Overview

LENZ market data

Price History

LENZ price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for LENZ. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

7 captured

LENZ Therapeutics Announces Availability Of VIZZ Through Telehealth Platform · Jul 6, 2026, 12:25 PM

8-K filing — LENZ Therapeutics, Inc. (LENZ) · Jul 2, 2026, 9:00 PM

LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst · Jun 24, 2026, 5:45 PM

LENZ Therapeutics And Arrotex Pharma Announce Exclusive License And Commercialization Agreement For Arrotex To Register And Commercialize VIZZ For Treatment Of Presbyopia In Australia And New Zealand · Jun 24, 2026, 12:40 PM

Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20 · May 13, 2026, 6:48 PM

Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight · May 11, 2026, 5:10 PM

Earnings Scheduled For May 11, 2026 · May 11, 2026, 11:11 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock